SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is trending following a second FDA Complete Response Letter for its EBVALLO cancer therapy, which now cites concerns over clinical trial design despite previously resolved manufacturing issues. The community is expressing significant frustration over the FDA's unexpected change in position and questioning the need for a new trial, especially given the drug's existing approval in Europe.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending following recent developments, including Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 weight loss pill which is notably unavailable on HIMS's platform, compounded by an analyst downgrade citing elevated 2026 investment outlook. This has ignited a split in community sentiment, with many questioning HIMS's competitive moat, while others actively buy the dip, asserting confidence in the company's broader personalized healthcare platform and vertical integration for long-term growth.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively trending as its advanced agentic and voice AI technology showcased at a recent major tech conference generated significant buzz, leading to new partnerships in the automotive and robotics sectors. The community is heavily discussing the stock's high short interest, anticipating a potential squeeze, and highlighting its strong revenue growth and strategic position within the expanding AI market.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax (ABVX) is trending due to heightened speculation surrounding a potential takeover by Eli Lilly and other major pharmaceutical companies, with reports from French media and government sources fueling the buzz. The community is actively discussing an impending bidding war and significant premiums for its promising ulcerative colitis drug, obefazimod, which has demonstrated strong Phase 3 data. This innovative treatment positions Abivax as a highly attractive target in the competitive inflammatory bowel disease market.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following strong preliminary financial results, which exceeded revenue expectations and highlighted record total contract value with high net revenue retention. This news, driven by significant growth in its diagnostics segment, is fueling community discussion around the company's strategic position in AI-powered oncology and precision medicine. Investors are actively debating the sustainability of its growth trajectory and valuation after substantial recent share appreciation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after announcing preliminary quarterly and full-year results that significantly beat revenue expectations, sparking strong bullish sentiment across the community. Investors are keenly discussing the impressive growth, coupled with high analyst price targets and the potential for a rally driven by the stock's low free float. However, some continue to voice concerns regarding the company's cash reserves and the ongoing risk of dilution.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to its ongoing transformation into a technology-driven e-commerce giant, prominently featuring new AI partnerships with Google's Gemini and an expansion of drone delivery services. Community discussions highlight its upcoming inclusion in the Nasdaq-100, affirming its strategic shift, while also debating whether its valuation aligns with these evolving retail fundamentals.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending as community discussion highlights its ultra-low share float and significant short interest, creating strong speculation for a potential short squeeze. Traders are actively drawing comparisons to past high-volatility runners like SMX, fueled by its presence on the Reg SHO list, high cost to borrow, and anticipation of upcoming earnings and contract news as potential catalysts.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending as the community reacts to the anticipated FDA approval of ORLADEYO oral pellets for pediatric hereditary angioedema patients, a positive development met with frustration over the stock's lack of upward movement. Investors are actively debating the company's recent conservative 2026 revenue guidance, despite a 9% wholesale acquisition cost increase and growing revenue for its flagship HAE treatment. The sentiment is further shaped by the recent CEO transition, with many hoping new leadership will address the stock's perceived undervaluation amid ongoing market manipulation claims.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending following a significant strategic collaboration for global expansion of its lead oncology therapy. The community is buzzing about the strong commercial performance and impressive clinical data for its core assets, solidifying a "best-in-class" perception and fueling acquisition speculation within an active biotech market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ENDRAs TAEUS Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (ENDRA or the Company), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new...

ENDRA Feasibility Study Demonstrates TAEUS Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (ENDRA or the Company), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease...

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease...

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and...

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition

MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.

ENDRA Life Sciences (NDRA) on Monday announced an aggregate of $4.9 million in commitments for a private placement, which was led by institutional and cryptocurrency investors.The investors have agreed to buy 744,340 shares of common stock or prefunded warrants, and accompanying warrants under the agreement, Endra said. If all warrants are fully exercised for cash, the company will receive up to $14.4 million in proceeds, it said. The offering is expected to close on or about October 14. &nbsp;The proceeds of the placement will be used to launch a digital asset treasury strategy managed by digital asset manager Arca Investment Management, the company said. ENDRA also intends to accumulate cryptocurrency and complete the TAEUS pilot validation imaging study focused on certain chronic liver conditions. Thermo Acoustic Enhanced UltraSound, or TAEUS, is a technology being developed by the company to assess tissue fat content and monitor tissue ablation during minimally invasive procedures.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251013346843/en/ENDRA-Life-Sciences-Announces-At-Market-Private-Placement-of-Up-to-%2414.4-Million-to-Launch-Digital-Asset-Treasury-Strategy-Managed-by-Leading-Crypto-Asset-Manager-Arca">announced</a> on Monday that it intends to add Arca’s Chief Investment Officer, Jeff Dorman, to its Digital Asset Advisory Board. The firm believes its new digital asset treasury strategy can compound returns and create flexible income to reinvest into cryptocurrency.<a href="https://stocktwits.com/symbol/NDRA">NDRA shares</a> traded 24% higher at the time of writing. On Stocktwits, retail sentiment around the stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.NDRA stock is up by 28% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-tvardi-therapeutics-stock-plummet-pre-market/ch6SK9gR3ki">Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

What’s Driving The Rally In NDRA Stock Today?

The company announced $4.9 million in commitments for a private placement led by institutional and cryptocurrency investors to be used to launch a digital asset treasury strategy.

Equity

The company announced $4.9 million in commitments for a private placement led by institutional and cryptocurrency investors to be used to launch a digital asset treasury strategy.


Pulse Biosciences Unveils Promising First-in-Human Data for nPulse

PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

ENDRA Life Sciences Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

NDRA
ENDRA Life Sciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NDRA News

NDRAENDRA Life Sciences Inc